Related Experiment Videos
Pharmacogenomics and reducing the frequency of adverse drug events
Pharmacogenomics
|January 9, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Novel association of NAV3 with dilated cardiomyopathy and its role in cardiac fibrosis.
American journal of physiology. Heart and circulatory physiology·2026
Alcohol use disorder-associated gene FNDC4 alters glutamatergic and GABAergic neurogenesis in neural organoids.
The Journal of clinical investigation·2026
Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.
The Journal of clinical investigation·2025
Comprehensive Characterization of Antidepressant Pharmacogenetics: A Systematic Review of Studies in Major Depressive Disorder.
Clinical and translational science·2025
Alcohol Use Disorder Associated Gene FNDC4 Alters Glutamatergic and GABAergic Neurogenesis.
bioRxiv : the preprint server for biology·2025
Mapping the development pipeline of genomic point-of-care tests: a horizon scan.
Pharmacogenomics·2026
Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.
Endocrinology, diabetes & metabolism·2026
Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis.
The Cochrane database of systematic reviews·2026
Synthesis of mannosides as potential inhibitors of PIMs biosynthesis in mycobacteria.
Organic & biomolecular chemistry·2026